Highlights Beam Therapeutics Inc.

Equities

BEAM

US07373V1052

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 13/02/2026 GMT			5-day change	1st Jan Change
27.92 ^USD	+3.68%		+2.35%	+0.72%

02-05	Beam Therapeutics Inc. Announces Resignation of Carole Ho from the Board of Directors, Effective February 27, 2026	CI
01-14	Beam Therapeutics Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-13-2026 05:15 PM

Highlights

12-06	Beam Therapeutics Inc. Reports Updated Data from BEACON Phase 1/2 Trial of Ristoglogene Autogetemcel (risto-cel)	CI
11-04	Beam Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-04	Earnings Flash (BEAM) Beam Therapeutics Inc. Reports Q3 Revenue $9.7M, vs. FactSet Est of $11.3M	MT
11-04	Beam Therapeutics Q3 net loss wider than expected on higher R&D expenses	RE
14/08/25	Beam Therapeutics Inc. Announces U.S. FDA Regenerative Medicine Advanced Therapy Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease	CI
05/08/25	Beam Therapeutics Q2 Net Loss Narrows, Revenue Falls	MT
05/08/25	Beam Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
05/08/25	Beam Therapeutics Q2 net loss widens more than expected	RE
05/08/25	Earnings Flash (BEAM) Beam Therapeutics Posts Q2 $1 Loss, vs. FactSet Est of $1.11 Loss	MT
05/08/25	Earnings Flash (BEAM) Beam Therapeutics Inc. Reports Q2 Revenue $8.5M, vs. FactSet Est of $12.8M	MT
05/08/25	Beam Therapeutics Provides an Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency	CI
13/06/25	Beam Therapeutics Inc. Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease at European Hematology Association 2025 Congress	CI
03/06/25	Beam Therapeutics Says Potential Sickle Cell Therapy Receives FDA Orphan Drug Designation	MT
29/05/25	Beam Therapeutics Says US FDA Granted Orphan Drug Designation to BEAM-302	MT
29/05/25	Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted To BEAM-302 For The Treatment Of Alpha-1 Antitrypsin Deficiency (AATD)	RE
14/05/25	Beam Therapeutics Inc to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association 2025 Congress	CI
12/05/25	Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency	CI
06/05/25	Beam Therapeutics Shares Fall After Q1 Net Loss Widens	MT
06/05/25	Earnings Flash (BEAM) Beam Therapeutics Posts Q1 License and Collaboration Revenue $7.5M	MT
06/05/25	Earnings Flash (BEAM) Beam Therapeutics Posts Q1 Loss $1.24, vs. FactSet Est of -$1.18	MT
06/05/25	Beam Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
05/04/25	Beam Therapeutics Inc. Presents Additional Data for Beam-302 in Alpha-1 Antitrypsin Deficiency At 2025 Alpha-1 Foundation 7Th Global Research Conference and 10Th Patient Congress	CI
27/03/25	Beam Therapeutics Inc. Announces Clearance of Investigational New Drug Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency by the United States (U.S.) Food and Drug Administration	CI
10/03/25	Beam Therapeutics Prices $500 Million Share, Warrant Offering	MT
10/03/25	Beam Therapeutics Inc. Announces Positive Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1 Antitrypsin Deficiency	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Highlights Beam Therapeutics Inc.

Equities

BEAM

US07373V1052

Biotechnology & Medical Research

Highlights

Filters